• Thursday, May 18th, 2017
    Biotechnology Reports – Dusquetide: Reduction in Oral Mucositis associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients
  • Thursday, April 27th, 2017
    BioWorld Today Ricin Toxin Program Review

    In a recent article in BioWorld Today, the Soligenix ricin toxin vaccine program was reviewed, including comments from Dr. Oreola Donini, Chief Scientific Officer of Soligenix.

    View the article here.

  • Monday, April 24th, 2017
    The Wall Street Transcript Interview

    Q&A with Dr. Christopher J. Schaber, President & CEO
    Read the interview (pdf)

  • Friday, April 7th, 2017
    Dr. Christopher J. Schaber’s Interview with Ashton Tweed

    In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the company’s rare disease business with Ashton Tweed for their CEO Leadership Series.

    Read the publication

  • Wednesday, March 15th, 2017
    Dr. Christopher J. Schaber’s Interview with OneMed Sentinel

    Soligenix, Inc. –  In this interview,  Dr. Christopher J. Schaber, President and CEO, discusses the company’s rare disease business, including key Phase 3 clinical programs and biodefense with The Sentinel’s Brett Johnson.

    Read Publication Here.

  • Monday, February 27th, 2017
    Forbes Custom – Rising to the Challenges of Rare Disease Treatment

    Soligenix, Inc. – Rising to the Challenges of Rare Disease Treatment, has been profiled in the February 2017 edition of Forbes Custom. In this profile, Dr. Christopher J. Schaber, President and CEO, discusses the Company’s pipeline and potential.

    Read the Publication

  • Wednesday, October 19th, 2016
    Journal of Biotechnology – Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study

    The publication of positive clinical results consistent with preclinical data

    Read the publication (pdf)

  • Monday, September 12th, 2016
    Equities.com – Soligenix (SNGX) Broadens Patent and Strikes Licensing Deal in China for Cancer-Fighting Drug

    Equities.com – Soligenix (SNGX) Broadens Patent and Strikes Licensing Deal in China for Cancer-Fighting Drug

    Read the article

  • Monday, June 13th, 2016
    Soligenix on The Price of Business Radio Show

    Dr. Christopher J. Schaber, President & Chief Executive Officer of Soligenix, Inc. recently discussed the Company with The Price of Business radio show. Click here to listen to the interview.

  • Tuesday, May 10th, 2016
    Soligenix on IDR technology and SGX942

    Dr. Oreola Donini, Chief Scientific Officer of Soligenix, Inc. recently discussed the IDR technology and SGX942 with two publications.

    Read the article in European Pharmaceutical Review

    Read the article in Drug Target Review

  • Monday, May 2nd, 2016
    The Life Sciences Report – Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need

    Dr. Christopher J. Schaber, President & CEO discusses the pipeline with The Life Sciences Report

    Read the article

  • Friday, April 29th, 2016
    Journal of Biotechnology – A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy

    The publication of data demonstrating the mechanism and broad-spectrum activity of dusquetide in preclinical bacterial infection models

    Read the publication (pdf)

  • Wednesday, October 28th, 2015
    NJBIZ – Impacting the world: Soligenix discovery could dramatically change vaccinations

    Dr. Christopher J. Schaber, President & CEO discusses ThermoVax™ technology and the vaccine market
    Read the article

  • Monday, October 26th, 2015
    The Wall Street Transcript

    Q&A with Dr. Christopher J. Schaber, President & CEO
    Read the Interview (pdf)

  • Monday, September 14th, 2015
    Scientia – Innate Defense Regulators: Novel Therapeutics for Emerging and Antibiotic-Resistant Diseases

    Dr. Oreola Donini, Chief Scientific Officer discusses SGX94
    Read the publication (pdf)

  • Friday, September 11th, 2015
    Drug Discovery News: On The Front Lines of Biodefense

    Q&A with Dr. Christopher J. Schaber, President & CEO
    Read the publication (pdf)

  • Tuesday, August 11th, 2015
    International Innovation – Bullseye: Targeting Cancer with Selective Innovations, Issue 190

    Drs. Schaber and Straube Discuss Treatment of Cutaneous T-Cell Lymphoma in Recent Publication
    Read the publication (pdf)

  • Sunday, August 2nd, 2015
    Soligenix Aims to Improve Quality of Life for Patients with Cutaneous Lymphoma

    Freelance author discusses SGX301 and CTCL on LymphomaInfo.net
    Read the article